OR WAIT 15 SECS
© 2025 MJH Life Sciences™ and Pharmaceutical Commerce - Biopharma Business News, Market Insights. All rights reserved.
Nicholas Saraceno is Editor of Pharmaceutical Commerce. He can be reached at nsaraceno@mjhlifesciences.com.
This episode of Pharma Pulse covers the CDC’s new individualized approach to COVID-19 vaccination and changes to chickenpox guidance for toddlers, new research showing how GLP-1 therapies can interfere with PET-CT imaging results, and the Third Circuit Court’s rejection of Novo Nordisk’s IRA challenge.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s episode, we’re covering updates from the CDC on vaccine recommendations, new clinical findings about GLP-1 therapies and imaging accuracy, and the latest legal ruling affecting Novo Nordisk and the Inflation Reduction Act.
From evolving vaccine strategies and diagnostic insights to major legal shifts in pricing reform, these stories underscore how regulatory and clinical developments continue to reshape the pharmaceutical landscape.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.